Ipsen S.A.

Ipsen S.A. is a French biopharmaceutical company headquartered in Paris, specializing in the development and commercialization of transformative medicines across three core therapeutic areas: oncology, rare diseases, and neuroscience. Founded in 1929 by Dr. Henri Beaufour as a family business, it has evolved over nearly a century into a global mid-sized player with approximately 5,000 employees worldwide, maintaining an agile, entrepreneurial mindset while achieving broad reach—its products are registered in 88 countries and directly commercialized in over 30. Ipsen pioneered key innovations like Decapeptyl for hormone-influenced conditions such as prostate cancer, Dysport for neurological disorders including dystonia and spasticity, Somatuline for acromegaly and neuroendocrine tumors, and more recent additions like cabozantinib for renal cell carcinoma, palovarotene for rare bone diseases, and Bylvay for pediatric rare liver conditions through strategic acquisitions. The company drives a robust pipeline via partnerships with biotechs and academia, targeting high unmet needs in cancers of the kidney, liver, and thyroid; rare genetic disorders; and debilitating neurological conditions, while emphasizing patient access, sustainability, and R&D hubs in France, the UK, and the US. Ipsen's science-led, patient-driven strategy underscores its role in advancing specialty care and fostering scientific exchange through the independent Fondation Ipsen.